Claims for Patent: 10,632,114

Summary for Patent: 10,632,114

Title:	Pyruvate kinase activators for use in therapy
Abstract:	Described herein are methods for using compounds that activate pyruvate kinase.
Inventor(s):	Su; Shin-San Michael (Boston, MA), Dang; Lenny (Boston, MA)
Assignee:	Agios Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:	15/965,088
Patent Claims:	1. A method for treating sickle cell anemia in a subject comprising administering to the subject a therapeutically effective amount of (1) a compound or pharmaceutically acceptable salt thereof or (2) a pharmaceutically acceptable composition comprising a compound or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier wherein the compound is: ##STR00019## 2. A method for treating thalassemia in a subject comprising administering to the subject a therapeutically effective amount of (1) a compound or pharmaceutically acceptable salt thereof or (2) a pharmaceutically acceptable composition comprising a compound or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier wherein the compound is: ##STR00020## 3. The method of claim 2 wherein the thalassemia is beta-thalassemia. 4. A method for increasing the lifetime of red blood cells (RBCs) in need thereof comprising contacting blood with a therapeutically effective amount of (1) a compound or pharmaceutically acceptable salt thereof or (2) a pharmaceutically acceptable composition comprising a compound or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier wherein the compound is: ##STR00021## 5. The method of claim 4 wherein the compound, pharmaceutically acceptable salt thereof or pharmaceutically acceptable composition is administered to a subject in need thereof. 6. The method of claim 4 wherein the compound, pharmaceutically acceptable salt thereof or pharmaceutically acceptable composition is added directly to whole blood or packed red blood cells extracorporeally. 7. A method for regulating the levels of 2,3-diphosphoglycerate (2,3-DPG) levels in blood in need thereof comprising contacting blood with an effective amount of (1) a compound or pharmaceutically acceptable salt thereof or (2) a pharmaceutically acceptable composition comprising a compound or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier wherein the compound is: ##STR00022## 8. The method of claim 7 wherein the compound, pharmaceutically acceptable salt thereof or pharmaceutically acceptable composition is administered to a subject in need thereof. 9. The method of claim 7 wherein the compound, pharmaceutically acceptable salt thereof or pharmaceutically acceptable composition is added directly to whole blood or packed red blood cells extracorporeally. 10. A method for treating hemolytic anemia in a subject comprising administering to the subject a therapeutically effective amount of (1) a compound or pharmaceutically acceptable salt thereof or (2) a pharmaceutically acceptable composition comprising a compound or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier wherein the hemolytic anemia is selected from congenital anemia and hereditary spherocytosis and wherein the compound is: ##STR00023## 11. The method of claim 10 wherein the hemolytic anemia is congenital anemia. 12. The method of claim 10 wherein the hemolytic anemia is hereditary spherocytosis.